ArticleCancers2021

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer.

Taizo Uchimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.